Teva’s €1bn euro debut a hit with investors
Teva Pharmaceutical Industries, the Israeli generic drug company, launched its first bond outside dollars on March 29, raising €1bn in a sale that found exceptionally strong demand, with a €7bn order book. BNP Paribas, HSBC and JP Morgan led the deal after a roadshow in the early part of the week.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts